SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?


To: Keith Feral who wrote (261)9/10/2007 10:10:05 AM
From: ggamerRead Replies (1) | Respond to of 418
 
6:05AM ADVENTRX Pharma announces ANX-514 clinical development plan affirmed by FDA (ANX) 2.32 : Co announces that it has received confirmation from the FDA regarding its proposed 505(b)(2) NewDrug Application regulatory path for ANX-514. The FDA has indicated that data from a single study of approx 28 patients that demonstrates the bioequivalence of ANX-514 and docetaxel is sufficient tosupport filing an NDA.